<DOC>
	<DOC>NCT00162097</DOC>
	<brief_summary>The purpose of the study was to assess the steady-state pharmacokinetics (PK) of efavirenz (EFV) in human immunodeficiency virus type 1 (HIV-1) infected subjects on stable antiretroviral regimens containing EFV, and having selected degrees of hepatic impairment or normal hepatic function.</brief_summary>
	<brief_title>Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>HIV1 infection with or without Hepatitis B or C infection Stable antiretroviral regimen containing efavirenz and nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) for at least 1 month Mild, moderate or severe hepatic impairment with hepatic cirrhosis Acute flare of hepatitis Positive pregnancy test for a female Significant acute medical illness in past 2 months Use of agents known to significantly affect liver metabolism Change in medications to treat a chronic disease in the past 2 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>